Values First Advisors Inc. Acquires 3,239 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Values First Advisors Inc. boosted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 9.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,921 shares of the company’s stock after acquiring an additional 3,239 shares during the period. Values First Advisors Inc.’s holdings in Elanco Animal Health were worth $535,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Comerica Bank purchased a new stake in shares of Elanco Animal Health during the third quarter valued at about $40,000. Advisory Services Network LLC lifted its position in shares of Elanco Animal Health by 104.1% during the first quarter. Advisory Services Network LLC now owns 5,204 shares of the company’s stock valued at $49,000 after buying an additional 2,654 shares during the last quarter. Captrust Financial Advisors lifted its position in shares of Elanco Animal Health by 57.0% during the first quarter. Captrust Financial Advisors now owns 2,690 shares of the company’s stock valued at $70,000 after buying an additional 977 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in shares of Elanco Animal Health during the fourth quarter valued at about $70,000. Finally, Covestor Ltd lifted its position in shares of Elanco Animal Health by 1,285.1% during the first quarter. Covestor Ltd now owns 2,978 shares of the company’s stock valued at $78,000 after buying an additional 2,763 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

Insider Transactions at Elanco Animal Health

In other news, Director R David Hoover acquired 20,000 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were acquired at an average price of $16.14 per share, with a total value of $322,800.00. Following the purchase, the director now directly owns 185,000 shares of the company’s stock, valued at $2,985,900. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 6.40% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the stock. BNP Paribas initiated coverage on shares of Elanco Animal Health in a research report on Thursday, December 7th. They set an “outperform” rating and a $18.00 price target for the company. Stifel Nicolaus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and increased their price objective for the company from $13.00 to $20.00 in a research report on Friday, January 5th. Morgan Stanley increased their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Jefferies Financial Group initiated coverage on shares of Elanco Animal Health in a research report on Tuesday, December 19th. They issued a “buy” rating and a $17.00 price objective for the company. Finally, TheStreet raised shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a research report on Friday, February 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and an average target price of $16.71.

Elanco Animal Health Stock Performance

ELAN traded up $0.11 during trading on Thursday, reaching $16.28. 2,321,901 shares of the company’s stock were exchanged, compared to its average volume of 4,410,575. Elanco Animal Health Incorporated has a 1 year low of $7.88 and a 1 year high of $16.88. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.75 and a quick ratio of 1.35. The stock has a market capitalization of $8.03 billion, a P/E ratio of -6.47, a price-to-earnings-growth ratio of 1.67 and a beta of 1.29. The company’s fifty day simple moving average is $15.75 and its 200-day simple moving average is $13.27.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Monday, February 26th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1 billion. Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. Elanco Animal Health’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.19 EPS. As a group, research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.